ME02684B - Jedinjenja i preparati protein kinaznih inhibitora - Google Patents

Jedinjenja i preparati protein kinaznih inhibitora

Info

Publication number
ME02684B
ME02684B MEP-2017-6A MEP617A ME02684B ME 02684 B ME02684 B ME 02684B ME P617 A MEP617 A ME P617A ME 02684 B ME02684 B ME 02684B
Authority
ME
Montenegro
Prior art keywords
compound
alkyl
halo
fluoro
substituted
Prior art date
Application number
MEP-2017-6A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John TELLEW
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02684(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ME02684B publication Critical patent/ME02684B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MEP-2017-6A 2009-08-28 2010-08-27 Jedinjenja i preparati protein kinaznih inhibitora ME02684B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11
EP14152945.3A EP2727918B1 (en) 2009-08-28 2010-08-27 Compounds and Compositions as Protein Kinase Inhibitors

Publications (1)

Publication Number Publication Date
ME02684B true ME02684B (me) 2017-06-20

Family

ID=42782253

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2017-6A ME02684B (me) 2009-08-28 2010-08-27 Jedinjenja i preparati protein kinaznih inhibitora
MEP-2014-94A ME01860B (me) 2009-08-28 2010-08-27 Jedinjenja i preparati protein kinaznih inhibitora

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2014-94A ME01860B (me) 2009-08-28 2010-08-27 Jedinjenja i preparati protein kinaznih inhibitora

Country Status (49)

Country Link
US (12) US8501758B2 (instruction)
EP (2) EP2727918B1 (instruction)
JP (2) JP5475888B2 (instruction)
KR (1) KR101413392B1 (instruction)
CN (2) CN103896921B (instruction)
AR (1) AR077975A1 (instruction)
AU (1) AU2010286569C1 (instruction)
BR (1) BR112012004453B1 (instruction)
CA (1) CA2771775C (instruction)
CL (1) CL2012000340A1 (instruction)
CO (1) CO6612222A2 (instruction)
CR (1) CR20120102A (instruction)
CU (1) CU24110B1 (instruction)
CY (3) CY1118452T1 (instruction)
DK (2) DK2727918T3 (instruction)
DO (1) DOP2012000051A (instruction)
EA (2) EA025222B1 (instruction)
EC (2) ECSP12011700A (instruction)
ES (2) ES2492499T3 (instruction)
GE (1) GEP20146102B (instruction)
GT (1) GT201200053A (instruction)
HN (1) HN2012000441A (instruction)
HR (2) HRP20140799T1 (instruction)
HU (3) HUE032847T2 (instruction)
IL (1) IL218084A (instruction)
IN (1) IN2012DN02469A (instruction)
JO (1) JO3002B1 (instruction)
LT (3) LT2727918T (instruction)
LU (2) LUC00102I2 (instruction)
MA (1) MA33604B1 (instruction)
ME (2) ME02684B (instruction)
MX (1) MX2012002546A (instruction)
MY (1) MY156259A (instruction)
NI (1) NI201200029A (instruction)
NL (1) NL300973I2 (instruction)
NO (2) NO2019011I1 (instruction)
NZ (1) NZ598924A (instruction)
PE (1) PE20120861A1 (instruction)
PL (2) PL2470526T3 (instruction)
PT (2) PT2470526E (instruction)
RS (2) RS55568B1 (instruction)
SG (2) SG10201405311TA (instruction)
SI (2) SI2470526T1 (instruction)
SM (3) SMT201700036T1 (instruction)
TN (1) TN2012000081A1 (instruction)
UA (1) UA112285C2 (instruction)
UY (1) UY32860A (instruction)
WO (1) WO2011025927A1 (instruction)
ZA (1) ZA201202020B (instruction)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
EP2776037B1 (en) * 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
SMT201800595T1 (it) * 2011-11-23 2019-01-11 Array Biopharma Inc Formulazioni farmaceutiche
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
UY34538A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
EA028135B1 (ru) 2012-03-28 2017-10-31 Дана-Фарбер Кэнсер Инститьют, Инк. Мутанты c-raf, придающие резистентность к ингибиторам raf
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
TR201904980T4 (tr) 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
WO2014027056A1 (en) 2012-08-17 2014-02-20 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
US20150283136A1 (en) * 2012-11-08 2015-10-08 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
CN112641787A (zh) 2013-03-21 2021-04-13 诺华股份有限公司 包含B-Raf抑制剂和第二抑制剂的组合疗法
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
SG11201509338QA (en) * 2013-05-30 2015-12-30 Plexxikon Inc Compounds for kinase modulation, and indications therefor
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN106211755B (zh) * 2013-12-20 2021-06-22 生物医学谷探索股份有限公司 使用erk和raf抑制剂的组合的癌症治疗
BR112016012506A8 (pt) * 2013-12-23 2018-01-30 Novartis Ag combinações farmacêuticas, seus usos, e uso de um portador de dados
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US10167279B2 (en) * 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
EP3191127A1 (en) 2014-09-13 2017-07-19 Novartis AG Combination therapies of egfr inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
MA42146A (fr) 2015-03-10 2021-04-21 Aduro Biotech Inc Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
MX2018005551A (es) 2015-11-03 2018-11-09 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1, y sus usos.
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
RU2759669C2 (ru) * 2016-06-03 2021-11-16 Аррэй Байофарма Инк. Фармацевтические комбинации
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化(上海)新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12076320B2 (en) 2018-07-12 2024-09-03 Shenzhen Targetrx, Inc. Diarylpyrazole compound, composition comprising same, and use thereof
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
US20220168250A1 (en) 2019-05-16 2022-06-02 Eli Lilly And Company TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFv6ooE COLORECTAL CANCER
EP4069692A1 (en) 2019-12-05 2022-10-12 Institut National de la Santé et de la Recherche Médicale (INSERM) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
JP7312335B2 (ja) 2020-06-09 2023-07-20 アレイ バイオファーマ インコーポレイテッド Braf関連疾患および障害を処置するための4-オキソ-3,4-ジヒドロキナゾリノン化合物
US20230303551A1 (en) 2020-08-13 2023-09-28 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN117642166A (zh) 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
CN116396222A (zh) * 2023-04-10 2023-07-07 上海睿腾医药科技有限公司 一种康奈非尼中间体1-(3-氨基-1-异丙基-1h-吡唑-4-基)乙-1-酮的合成方法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6281193B1 (en) 1996-05-23 2001-08-28 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
BR9809147A (pt) 1997-05-22 2000-08-01 Searle & Co Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
ES2398643T3 (es) 1999-12-23 2013-03-20 Mayne Pharma International Pty Ltd. Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
MXPA04003878A (es) 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
DE60222804T2 (de) 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
PL230179B1 (pl) 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
KR20060097000A (ko) 2003-09-23 2006-09-13 노파르티스 아게 화학요법제와 vegf 수용체 저해제의 배합물
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
KR20060127032A (ko) 2004-01-09 2006-12-11 노파르티스 아게 Igf―ir 억제제로서의페닐-[4-(3-페닐-1h-피라졸-4-일)-피리미딘-2-일]-아민유도체
AU2005254982B2 (en) 2004-06-10 2008-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20090306107A1 (en) 2005-03-17 2009-12-10 Novartis Ag Organic Compounds
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
CN102198273A (zh) 2005-08-22 2011-09-28 诺瓦提斯公司 包含pH依赖性药物、pH调节剂和阻滞剂的药物组合物
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
KR20080108516A (ko) 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
JP2010502743A (ja) 2006-09-11 2010-01-28 キュリス,インコーポレイテッド 抗増殖薬剤としての多機能性低分子
EP2068880B1 (en) 2006-09-18 2012-04-11 Boehringer Ingelheim International GmbH Method for treating cancer harboring egfr mutations
CN103739595A (zh) 2006-10-02 2014-04-23 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US20100087464A1 (en) * 2006-10-06 2010-04-08 Irm Llc Protein kinase inhibitors and methods for using thereof
MX2009008584A (es) 2007-02-15 2009-08-18 Novartis Ag Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009016460A2 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
AU2008313622A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of N-aryl urea-based drugs
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2274300A2 (en) 2008-03-21 2011-01-19 Novartis AG Novel heterocyclic compounds and uses therof
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8541575B2 (en) * 2008-07-24 2013-09-24 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
WO2010014611A1 (en) 2008-07-28 2010-02-04 Gilead Colorado, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
EP2350052B1 (en) 2008-09-29 2014-08-13 Boehringer Ingelheim International GmbH Antiproliferative compounds
AU2009300866B2 (en) 2008-10-07 2013-03-28 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20110293750A1 (en) * 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
EP2373664B1 (en) * 2008-12-19 2013-06-12 Nerviano Medical Sciences S.r.l. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
WO2010145998A1 (en) * 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
JP5806239B2 (ja) 2010-01-27 2015-11-10 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ プロテインキナーゼ阻害剤としての3,4−ジアリールピラゾールのスルホンアミド誘導体
KR20130053404A (ko) 2010-03-30 2013-05-23 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
CN110279861A (zh) 2011-03-21 2019-09-27 瓦尔库里亚公司 包括hdac抑制剂以及类固醇的药用组合物及其用途
BR112013032125A2 (pt) 2011-06-14 2016-12-13 Novartis Ag combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
SMT201800595T1 (it) 2011-11-23 2019-01-11 Array Biopharma Inc Formulazioni farmaceutiche
US20150283136A1 (en) 2012-11-08 2015-10-08 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
SMT201700036T1 (it) 2017-03-08
SG10201405311TA (en) 2014-09-26
US10005761B2 (en) 2018-06-26
HK1167390A1 (en) 2012-11-30
JP5475888B2 (ja) 2014-04-16
US9314464B2 (en) 2016-04-19
BR112012004453A8 (pt) 2021-06-08
PE20120861A1 (es) 2012-07-14
EP2727918B1 (en) 2016-10-12
ES2492499T3 (es) 2014-09-09
US20230116233A1 (en) 2023-04-13
HN2012000441A (es) 2015-01-05
NO2019011I1 (no) 2019-03-05
IL218084A (en) 2016-11-30
PT2470526E (pt) 2014-09-01
JO3002B1 (ar) 2016-09-05
CU20120034A7 (es) 2012-06-21
SI2727918T1 (sl) 2017-02-28
KR101413392B1 (ko) 2014-06-27
CU24110B1 (es) 2015-07-30
US20160280686A1 (en) 2016-09-29
DOP2012000051A (es) 2012-05-31
CL2012000340A1 (es) 2012-08-17
LUC00101I2 (instruction) 2020-01-23
NZ598924A (en) 2013-07-26
MA33604B1 (fr) 2012-09-01
US20180297986A1 (en) 2018-10-18
TN2012000081A1 (en) 2013-09-19
CY2019013I1 (el) 2019-11-27
HUS1900013I1 (hu) 2019-04-29
GEP20146102B (en) 2014-05-27
US20160280687A1 (en) 2016-09-29
BR112012004453B1 (pt) 2022-04-26
LT2727918T (lt) 2017-01-25
ME01860B (me) 2014-12-20
CN103896921B (zh) 2016-02-24
IL218084A0 (en) 2012-04-30
SMT201400133B (it) 2014-11-10
EP2470526A1 (en) 2012-07-04
HUE032847T2 (hu) 2017-11-28
UY32860A (es) 2011-03-31
AU2010286569B2 (en) 2013-10-10
AU2010286569A1 (en) 2012-04-12
IN2012DN02469A (instruction) 2015-08-21
SI2470526T1 (sl) 2014-09-30
HUS1900012I1 (hu) 2019-04-29
ES2610825T3 (es) 2017-05-03
CN102725283A (zh) 2012-10-10
EP2470526B1 (en) 2014-05-28
SMT201700036B (it) 2017-03-08
EA201200373A1 (ru) 2012-09-28
JP2013503186A (ja) 2013-01-31
EA025222B1 (ru) 2016-12-30
US20180297985A1 (en) 2018-10-18
ECSP12011700A (es) 2012-03-30
AU2010286569C1 (en) 2019-11-28
USRE49556E1 (en) 2023-06-20
CY2019014I2 (el) 2019-11-27
HRP20170005T1 (hr) 2017-03-10
SG178351A1 (en) 2012-03-29
US20160120866A1 (en) 2016-05-05
RS53489B1 (en) 2015-02-27
UA112285C2 (uk) 2016-08-25
MY156259A (en) 2016-01-29
RS55568B1 (sr) 2017-05-31
US20160122324A1 (en) 2016-05-05
PL2470526T3 (pl) 2014-10-31
PL2727918T3 (pl) 2017-06-30
NL300973I2 (nl) 2022-05-05
US20160263113A1 (en) 2016-09-15
US9593100B2 (en) 2017-03-14
US20110306625A1 (en) 2011-12-15
JP2014098022A (ja) 2014-05-29
DK2470526T3 (da) 2014-08-25
CO6612222A2 (es) 2013-02-01
EP2727918A1 (en) 2014-05-07
AR077975A1 (es) 2011-10-05
CN102725283B (zh) 2014-02-26
MX2012002546A (es) 2012-04-11
ZA201202020B (en) 2012-12-27
KR20120062839A (ko) 2012-06-14
LTPA2019006I1 (lt) 2019-03-25
US9593099B2 (en) 2017-03-14
GT201200053A (es) 2014-03-27
LTC2470526I2 (lt) 2020-04-27
US20130296318A1 (en) 2013-11-07
WO2011025927A1 (en) 2011-03-03
US20200323852A1 (en) 2020-10-15
NI201200029A (es) 2012-05-29
CY2019013I2 (el) 2019-11-27
EA201500175A1 (ru) 2015-05-29
CY2019014I1 (el) 2019-11-27
LTPA2019005I1 (lt) 2019-03-25
LUC00102I2 (instruction) 2024-05-21
PT2727918T (pt) 2017-01-20
US10576080B2 (en) 2020-03-03
NL300973I1 (instruction) 2019-03-27
CA2771775A1 (en) 2011-03-03
CN103896921A (zh) 2014-07-02
DK2727918T3 (da) 2017-01-23
US9850230B2 (en) 2017-12-26
HRP20140799T1 (hr) 2014-11-07
NO2019012I1 (no) 2019-03-05
US10568884B2 (en) 2020-02-25
LUC00101I1 (instruction) 2019-02-13
CA2771775C (en) 2015-01-20
ECSP23004573A (es) 2023-04-28
US9850229B2 (en) 2017-12-26
CY1118452T1 (el) 2017-07-12
US8501758B2 (en) 2013-08-06
JP6045519B2 (ja) 2016-12-14
BR112012004453A2 (pt) 2021-03-09
CR20120102A (es) 2012-05-02

Similar Documents

Publication Publication Date Title
ME02684B (me) Jedinjenja i preparati protein kinaznih inhibitora
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
CN112867721A (zh) Sting激动性化合物
HRP20171748T1 (hr) 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba
MEP23808A (en) Pyridine[3,4-b]pyrazinones
MY168753A (en) Pyrazine derivatives as enac blockers
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
TR201906123T4 (tr) P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
SE0402735D0 (sv) Novel compounds
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
RU2012120288A (ru) Новые производные нафтиридина и их применение в качестве ингибиторов киназы
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
JP2008525417A5 (instruction)
IL198226A0 (en) 2-[l-phenyl-5-hydroxy-4alpha-methyl
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NZ616300A (en) Novel rock inhibitors
PH12015500063B1 (en) Azaindole derivatives which act as pi3k inhibitors
MX2016014574A (es) El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
RU2014145285A (ru) Ингибиторы протеинкиназ